GeneFerm Biotechnology Co (ROCO:1796) Total Receivables: NT$98.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1796 GeneFerm Biotechnology Co Ltd ROCO:1796
65 GF Score
Price NT$31.40
GF Value NT$59.04
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is GeneFerm Biotechnology Co Total Receivables?

GeneFerm Biotechnology Co ROCO:1796 -1.26% 65 Total Receivables is NT$98.2 Mil as of Dec. 2025. GuruFocus rates ROCO:1796 with a GF Score™ of 65/100 and a GF Value™ of NT$59.04 (Significantly Undervalued). The stock has 6 warning signs investors should review.

GeneFerm Biotechnology Co's Total Receivables for the quarter that ended in Dec. 2025 was NT$98.2 Mil.

GeneFerm Biotechnology Co Total Receivables Related Terms

GeneFerm Biotechnology Co Total Receivables Historical Data

* Premium members only.

The historical data trend for GeneFerm Biotechnology Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneFerm Biotechnology Co Total Receivables Chart

GeneFerm Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.89 121.44 117.75 101.86 98.19

GeneFerm Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.86 89.80 104.29 91.64 98.19
ROCO:1796
65GF Score
GeneFerm Biotechnology Co Ltd ROCO:1796
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneFerm Biotechnology Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of NT$98.2 Mil mean?
GeneFerm Biotechnology Co (ROCO:1796) has a Total Receivables of NT$98.2 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GeneFerm Biotechnology Co and its competitors.
Is GeneFerm Biotechnology Co's Total Receivables too high?
GeneFerm Biotechnology Co's current Total Receivables is NT$98.2 Mil. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's Total Receivables compare to ZTS and UTHR?
GeneFerm Biotechnology Co's Total Receivables of NT$98.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GeneFerm Biotechnology Co and its competitors. GeneFerm Biotechnology Co's current Total Receivables is NT$98.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.04, compared to a current price of NT$31.40 — trading 46.8% below its estimated fair value. The current Total Receivables is NT$98.2 Mil. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current Total Receivables is NT$98.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?

Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued. The current stock price of NT$31.40 is trading 46.8% below its estimated GF Value™ of NT$59.04. GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.

Key valuation signals for ROCO:1796:

  • Total Receivables: NT$98.2 Mil
  • GF Value™: NT$59.04 vs. price of NT$31.40 (46.8% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneFerm Biotechnology Co Business Description

Address No. 33, Xingong Road, Xinying District, Tainan, TWN, 74144
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score

Get the complete analysis for ROCO:1796

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.40
Price
NT$59.04
GF Value